Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if NKTX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
136 filers reported a long position in NKTX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $30.6M | 10.8M | Unchanged |
| BlackRock, Inc. | $17.8M | 6.3M | +39.7% |
| NEA Management Company, LLC | $10.1M | 3.6M | Unchanged |
| Samsara BioCapital, LLC | $9.9M | 3.5M | Unchanged |
| SR ONE CAPITAL MANAGEMENT, LP | $9.4M | 3.3M | Unchanged |
| GSK plc | $8.9M | 3.2M | Unchanged |
| Monaco Asset Management SAM | $6.7M | 2.4M | -5.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.3M | 2.2M | +10.7% |
| CITADEL ADVISORS LLC | $6.2M | 2.2M | +21.9% |
| TWO SIGMA INVESTMENTS, LP | $5.3M | 1.9M | -8.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.